Article

Alimera Sciences, CDS develop DME treatment

Atlanta—Alimera Sciences Inc. and Control Delivery Systems Inc. (CDS) will work together to develop and market a pharmacologic treatment for diabetic macular edema (DME).

Atlanta-Alimera Sciences Inc. and Control Delivery Systems Inc. (CDS) will work together to develop and market a pharmacologic treatment for diabetic macular edema (DME).

The potential treatment involves injecting a tiny implant into the vitreous via a 25-gauge needle. The implant is designed to deliver a drug to the back of the eye for up to 3 years. The companies are working with the FDA to initiate clinical trials to determine its effectiveness as an alternative to laser photocoagulation therapy.

The deal also gives Alimera Sciences the option to develop three additional products with CDS' drug delivery technology.

Meanwhile, Alimera Sciences has named Phil Tracy as chairman of its board of directors. Tracy was president and chief executive officer of Burroughs Wellcome Co. from 1989 to 1995, when the pharmaceutical company boasted $1.2 billion in sales and 5,000 employees prior to its 1995 merger with Glaxo Inc. He is a venture partner with Intersouth Partners, and has been a member of Alimera Sciences' board of directors since July.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
© 2025 MJH Life Sciences

All rights reserved.